Virtual conference

BeiGene to Present at Cowen’s 42nd Annual Virtual Healthcare Conference | Business

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–March 1, 2022–

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a science-driven global biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide , today announced that the company will be participating in the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 9:50 a.m. ET.

BeiGene is a science-driven global biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of over 40 clinical candidates, we are accelerating the development of our diverse portfolio of novel therapies through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

CONTACT: Contact with investors

KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC MASSACHUSETTS

INDUSTRY KEYWORD: GENETIC BIOTECHNOLOGY HEALTH CLINICAL TRIALS

Copyright BusinessWire 2022.

PUBLISHED: 03/01/2022 05:30/DISC: 03/01/2022 05:31

Copyright BusinessWire 2022.